Navigation Links
2 BUSM faculty receive Alzheimer's disease grants

(Boston) - David Harris, MD, PhD, chair and professor of biochemistry and Benjamin Wolozin, MD, PhD, professor of pharmacology and experimental therapeutics and neurology at Boston University School of Medicine (BUSM), have received Massachusetts Neuroscience Consortium (MNC) Awards. Each will receive a $250,000 grant allowing their teams to explore new therapeutic targets for Alzheimer's disease.

Harris is developing a novel approach to the therapy of Alzheimer's disease based on targeting a newly recognized molecular pathway responsible for neurodegeneration. Based on this approach, drug compounds have the potential to overcome some of the limitations of existing medications. Current treatments are largely ineffective and do not halt the cognitive decline associated with the disease.

"This award will significantly enhance our ability to develop improved therapies for Alzheimer's disease by allowing us to interact with industry partners, which is an important element of drug development," said Harris.

Harris' laboratory at BUSM investigates the molecular and cellular mechanisms underlying two classes of human neurodegenerative disorders: prion diseases and Alzheimer's disease. Prion and Alzheimer's diseases are part of a larger group of neurodegenerative disorders, including Parkinson's, Huntington's and several other diseases.

Wolozin is developing compounds that inhibit aggregation and toxicity caused by TDP-43, a protein that forms aggregates in Alzheimer's disease as well as other diseases, such as amyotrophic lateral sclerosis and frontotemporal dementia. He is known for his Alzheimer's research, which focuses on the role of cholesterol in Alzheimer's disease and investigating mechanisms in which statins may impact the pathophysiology of the disease.

"This grant emphasizes the importance of collaboration between BUSM and development programs at major pharmaceutical companies in the Boston area," said Wolozin.

Principal Investigator of the project, Wolozin is working with Marcie Glicksman, PhD, and Kevin Hodgetts, PhD, co-directors of the Laboratory for Drug Discovery in Neurodegeneration (LDDN) at Brigham and Women's Hospital. The teams will divide the work between biology and chemistry.


Contact: Gina Orlando
Boston University Medical Center

Related medicine news :

1. Faculty of 1000 announces partnership between F1000Prime and docwise
2. Creighton University Welcomes New Faculty Member to Master of Public Health Program
3. Faculty List for Continuing Medical Education (CME) Conference 17th Annual Conference on Hypertension, Diabetes and Dyslipidemia Released by Continuing Education Company
4. 8th edition of LSUHSC facultys textbook published
5. Concordia University, Nebraska Faculty Member Headed to Guatemala for Mission Trip
6. Renowned medical genetics pioneer to join LA BioMed faculty
7. MCG faculty member, former hostage returns to Kuwait as Fulbright Scholar
8. Radiation Research Society honors 2 faculty
9. RIT receives $3.2 million award from the NSF to advance female faculty
10. Faculty from UCLA Center for Autism Research and Treatment receive multiple NIH awards
11. College biology faculty named Leadership Fellows
Post Your Comments:
(Date:11/30/2015)... , ... November 30, 2015 , ... Cycling, running, and ... take on extra meaning the morning of February 28, 2016. , That’s when ... Park and thousands will exercise to help children and families at Joe DiMaggio ...
(Date:11/30/2015)... ... November 30, 2015 , ... A ... of bacteria could be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of ... Their study showed that small molecule analogs that target the functions of SecA, ...
(Date:11/30/2015)... ... November 30, 2015 , ... Using a combination of two blood ... children and adults, according to a new study by researchers at the School of ... Children and Adults: Using Combinations of Blood Glucose Tests ,” published in Frontiers in ...
(Date:11/30/2015)... ... November 30, 2015 , ... International telepathology consultations can ... and KingMed Diagnostics researchers. Their review of more than 1,500 pathology ... pathologists resulted in significantly altered treatment plans for more than half of the ...
(Date:11/30/2015)... PHILADELPHIA (PRWEB) , ... November 30, 2015 , ... ... Philadelphia-based non-profit promoting breast and prostate cancer education and prevention—is joining forces with ... evening of philanthropy and Hollywood elegance on December 7, 2015 at the Union ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015 Cumberland Pharmaceuticals (CPIX), today announced that A.J. ... on December 3, 2015. TIME: 3:15p.m. ET LINK: ... LINK: --> DATE: Thursday, ... --> --> This ... invited to ask the company questions in real-time - both ...
(Date:11/30/2015)... 2015 Varian Medical Systems (NYSE: VAR ) has ... with Apollo Hospitals Group, the largest hospital chain in ... radiation technologists in the country. The MoU was signed by Dr. ... Ashok Kakkar , Varian,s India managing ... India , Varian intends to deploy its Access to Care ...
(Date:11/30/2015)... LONDON and BOSTON , ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> PFE ) to ... to 10 G protein-coupled receptor (GPCR) targets across multiple ... clinical-stage GPCR structure-guided drug discovery and development company and ...
Breaking Medicine Technology: